It is well established that screening for colorectal cancerwith the fecal occult-blood test significantly lowers the rateof death from the disease.1 The report by Mandel et al.2 inthis issue of the Journal suggests that it also prevents cancer,reaffirming prior research about the benefits of detecting adenomatouspolyps.3 The mounting evidence that early detection saves liveshas sharpened the consensus among professional groups that screeningfor colorectal cancer should begin routinely at the age of 50.4
The current debate centers on which tests to use, at what ages,and how often. Each of the tests fecal . . . [Full Text of this Article]
References
This article has been cited by other articles:
Levin, T. R., Zhao, W., Conell, C., Seeff, L. C., Manninen, D. L., Shapiro, J. A., Schulman, J.
(2006). Complications of Colonoscopy in an Integrated Health Care Delivery System. ANN INTERN MED
145: 880-886
[Abstract][Full Text]
Roessler, M., Rollinger, W., Mantovani-Endl, L., Hagmann, M.-L., Palme, S., Berndt, P., Engel, A. M., Pfeffer, M., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., Tacke, M.
(2006). Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-based Approach for Data Analysis. Mol. Cell. Proteomics
5: 2092-2101
[Abstract][Full Text]
Roessler, M., Rollinger, W., Palme, S., Hagmann, M.-L., Berndt, P., Engel, A. M., Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., Tacke, M.
(2005). Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for Colorectal Cancer. Clin. Cancer Res.
11: 6550-6557
[Abstract][Full Text]
Hawk, E. T., Levin, B.
(2005). Colorectal Cancer Prevention. JCO
23: 378-391
[Abstract][Full Text]
Zapka, J. G., Lemon, S. C., Puleo, E., Estabrook, B., Luckmann, R., Erban, S.
(2004). Patient Education for Colon Cancer Screening: A Randomized Trial of a Video Mailed before a Physical Examination. ANN INTERN MED
141: 683-692
[Abstract][Full Text]
Whynes, D. K.
(2002). The economic case for faecal occult blood screening. Ann Oncol
13: 1953-1955
[Full Text]
Anderson, W. F., Guyton, K. Z., Hiatt, R. A., Vernon, S. W., Levin, B., Hawk, E.
(2002). Colorectal Cancer Screening for Persons at Average Risk. JNCI J Natl Cancer Inst
94: 1126-1133
[Full Text]
Pignone, M., Saha, S., Hoerger, T., Mandelblatt, J.
(2002). Cost-Effectiveness Analyses of Colorectal Cancer Screening: A Systematic Review for the U.S. Preventive Services Task Force. ANN INTERN MED
137: 96-104
[Abstract][Full Text]
Pignone, M., Rich, M., Teutsch, S. M., Berg, A. O., Lohr, K. N.
(2002). Screening for Colorectal Cancer in Adults at Average Risk: A Summary of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED
137: 132-141
[Abstract][Full Text]
Barry, M. J.
(2002). Fecal occult blood testing for colorectal cancer: a perspective. Ann Oncol
13: 61-64
[Abstract][Full Text]
Ransohoff, D. F., Sandler, R. S.
(2002). Screening for Colorectal Cancer. NEJM
346: 40-44
[Full Text]
Pesce, A.
(2001). Colorectal cancer screening. Fam Pract
18: 457-460
[Full Text]